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Although BRAF and MEK inhibitors have proven
clinical benefits in melanoma, most patients
develop resistance. We report a de novo MEK2-
Q60P mutation and BRAF gain in a melanoma
from a patient who progressed on the MEK inhibitor
trametinib and did not respond to the BRAF
inhibitor dabrafenib. We also identified the same
MEK2-Q60P mutation along with BRAF amplifica-
tion in a xenograft tumor derived from a second
melanoma patient resistant to the combination of
dabrafenib and trametinib. Melanoma cells chroni-
cally exposed to trametinib acquired concurrent
MEK2-Q60P mutation and BRAF-V600E amplifica-
tion, which conferred resistance to MEK and BRAF
inhibitors. The resistant cells had sustained MAPK
activation and persistent phosphorylation of S6K.
A triple combination of dabrafenib, trametinib, and
the PI3K/mTOR inhibitor GSK2126458 led to
sustained tumor growth inhibition. Hence, concur-
rent genetic events that sustain MAPK signaling
can underlie resistance to both BRAF and MEK
inhibitors, requiring novel therapeutic strategies to
overcome it.1090 Cell Reports 4, 1090–1099, September 26, 2013 ª2013 The AuINTRODUCTION
Melanoma is the most lethal skin cancer, and its incidence con-
tinues to increase worldwide. Deregulation of MAPK signaling is
a hallmark of melanoma. In particular, mutant BRAF-V600-
melanoma cells are dependent on MEK/ERK signaling (Ribas
and Flaherty, 2011; Solit et al., 2006). Based on improved overall
survival, two BRAF inhibitors (BRAFi), vemurafenib and dabra-
fenib, and the allosteric MEK inhibitor (MEKi) trametinib have
received Food and Drug Administration approval for the treat-
ment of metastatic BRAF-V600E (V600E) melanoma. Addition-
ally, trametinib in combination with dabrafenib significantly
improves progression-free survival compared to monotherapy
(Flaherty et al., 2012). Nevertheless, the long-term efficacy of
these compounds is limited by the emergence of drug resistance
(Sosman et al., 2012). Several mechanisms of resistance to
BRAFi have been identified (Abel et al., 2013; Das Thakur
et al., 2013; Johannessen et al., 2010; Nazarian et al., 2010;
Poulikakos et al., 2011; Roesch et al., 2013; Shi et al., 2012b;
Villanueva et al., 2010). Resistance to MEKi has been linked to
mutations in MAP2K1 (MEK1) (Emery et al., 2009; Wagle et al.,
2011; Trunzer et al., 2013) and a MAP2K2 (MEK2) E207K muta-
tion was identified in a melanoma cell line with decreased
sensitivity to selumetinib (Nikolaev et al., 2012). Given the
heterogeneity of melanoma, additional resistance mechanisms
are likely to arise. Moreover, it is not yet known if the same
mechanisms underlie resistance to combined BRAF and MEKthors
(legend on next page)
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inhibition. As most patients with metastatic BRAF-V600Emutant
melanoma will be treated with BRAF and MEK inhibitors, delin-
eating the spectrum of resistance mechanisms is critical to
devise optimal therapeutic regimens.
RESULTS
A De Novo MEK2 Mutation and BRAF Gain Is Associated
with Resistance to MEK and BRAF Inhibitors
To identify genetic alterations associated with drug resistance in
clinical specimens, serial biopsies were obtained from a BRAF-
V600E metastatic melanoma patient enrolled on the trametinib
first-in-human study MEK111054 (Infante et al., 2012; Falchook
et al., 2012) prior to treatment with trametinib and at different
times after treatment initiation. Paired biopsies showed a phar-
macodynamic response with striking decreases in pERK and
Ki67 after 2 weeks of treatment (Figure S1A). The patient
achieved a confirmed partial response with 57% tumor reduc-
tion and remained on study for 36 weeks prior to discontinuation
due to disease progression (Figure 1A). A postprogression
biopsy was obtained from the same chest wall mass just
prior to enrollment in the dabrafenib first-in-human study
BRF112680. Sequenom analysis of the tumor samples demon-
strated a MAP2K2 c.179A > C p.Gln60Pro (MEK2-Q60P) muta-
tion in the postprogression sample, which was not present in
the trametinib predose or day 15 samples (Figure 1B). The
patient also had gain of the region on chromosome 7 containing
BRAF, in pretreatment, on-treatment, and progression samples
(Figure 1C). The patient’s best response while receiving dabra-
fenib was progressive disease at approximately week 8, sug-
gesting that the MEK2-Q60P mutation, and potentially the gain
of BRAF, conferred resistance to both MEK and BRAF inhibitors
in this patient.
Modeling Resistance to MEK and BRAF Inhibitors
In Vitro
We modeled the emergence of drug resistance in BRAF-V600E
melanoma cells by chronically exposing them to trametinib. Cells
chronically exposed to the MEK inhibitor (MR) were substantially
less sensitive to trametinib than the isogenic parental cells and
were cross-resistant to selumetinib (AZD6244), vemurafenib,
PLX4720, and dabrafenib (Figures 1D–1G and S1B–S1E; data
not shown). Viability in response to chemotherapy was similar
in parental and resistant sublines (Figure S1F). MEK and BRAF
inhibitors efficiently blocked ERK phosphorylation in the parental
but not in the resistant cells (Figures 1H, 1I, and S1G–S1K).Figure 1. A De Novo MEK2 Mutation in Trametinib-Resistant Melanom
(A) MRI images from a 62-year-old white male with metastatic melanoma, with
trametinib and at different times after treatment initiation. VLA, vertical long axis;
(B) Sequenom iPLEX assay depicting nucleotide determination on pretreatme
mutation. A, wild-type nucleotide; C, mutant nucleotide.
(C) Fold amplification of BRAF in human samples determined by qPCR. Norma
trametinib pretreatment; post-tx-Tram, progression on trametinib; pre-tx-Dabra,
(D–G) Melanoma cells were treated with MEK (D and E) or BRAF (F and G) inhibito
represented as mean ± SEM with n = 3.
(H and I) Mel1617 parental and trametinib-resistant (MR) sublines were treated
immunoblotting.
See also Figure S1.
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MAP2K2 mutation c.179A > C (MEK2-Q60P) as that observed
in the patient’s melanoma in two of the five resistant sublines
independently generated (Figure 2A; data not shown). The gluta-
mine at position 60 is located within a negative regulatory region
of MEK2, Helix A; substitutions of proline into the Helix A of
MEK1 have been shown to cause kinase activation (Emery
et al., 2009; Senawong et al., 2008; Wagle et al., 2011). A
sequence alignment of MEK1 and MEK2 reveals that the
MEK2-Q60P trametinib-resistant mutant identified in this study
is analogous to the MEK1-Q56P AZD6244-resistant mutant
identified by random insertion mutagenesis (Emery et al.,
2009). The structure of MEK1 bound in complex to ATP and
the allosteric MEK inhibitor AZD6244 reveals that the MEK1-
Q56 (MEK2-Q60) residue is in a regulatory A helix that sits
against the N-terminal kinase lobe that binds both ATP and the
allosteric inhibitor (Figure 2B). Residues within the A helix are
too far from ATP and inhibitor to interact directly with the ligands
but are close enough to the N-terminal kinase lobe to alter the
ATP binding site. We therefore propose that the MEK2-Q60P
drug-resistant mutation likely functions by allosterically altering
the ATP binding site in a way that increases the intrinsic kinase
activity of MEK2. Accordingly, pMEK and pERK levels were
3- and 20-fold higher in 293T cells ectopically expressing
MEK2-Q60P compared to WT MEK2 (Figure 2C; Table S1).
Melanoma cells ectopically expressing MEK2-Q60P required
higher concentrations of trametinib for MAPK inhibition;
PLX4720 had virtually no effect on pERK inhibition (Figures 2D
and 2E). Whereas overexpression of WT MEK2 did not alter the
effect of BRAF or MEK inhibitors on cell viability, overexpression
of MEK2-Q60P caused a >10-fold decrease in sensitivity to
these compounds (Figures 2F, 2G, and S2A). BRAFi hadminimal
effects on pMEK and pERK levels even in low serum conditions
(data not shown). These data indicate that MEK2-Q60P is asso-
ciated with an attenuated response to BRAF/MEK inhibitors and
does not require substantial mitogenic stimulation.
To further examine the role of MEK2-Q60P in modulating
sensitivity to MEK and BRAF inhibitors, we silenced MEK2 in
Mel1617-MR cells. MEK2 depletion partially restored sensitivity
to these drugs (Figures 2H–2K and S2B–S2E). In contrast,
silencing of MEK1 in Mel1617-MR had no significant effect on
MAPK activity and drug sensitivity (Figures S2F–S2M). Further-
more, silencing of MEK1/2 in parental cells had minimal effects
on drug sensitivity (Figures S2N–S2Q).
Considering that MEK2 depletion in resistant cells only
partially restored drug sensitivity, we postulated that additionala
involvement of the lungs, chest wall, heart, and liver prior to treatment with
SAX, short axis.
nt and at progression samples. Specific assay depicted is for MEK2-Q60P
l DNA control; FFPE, formalin-fixed paraffin-embedded sample; pre-tx-Tram,
dabrafenib pretreatment. Error bars denote SD for four replicate PCRs.
rs for 72 hr. Cell viability was calculated relative to the untreated cells. Data are
with trametinib (H) or PLX4720 (I) for 20 hr. Protein lysates were analyzed by
thors
(legend on next page)
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factors could be underlying resistance to BRAF/MEK inhibitors in
our trametinib-resistant cells. To explore this possibility, we per-
formed array-based comparative genomic hybridization (aCGH).
The resistant cells had a localized 20-fold amplification on chro-
mosome 7, targeting the BRAF locus (Figure 3A). The mutant
BRAF-V600E allele was amplified compared to the wild-type
allele with a mutant: wild-type ratio of 10:1; BRAF mRNA and
protein levels were also higher (Figures 3B and 3C). Depletion
of BRAF to levels equivalent to those found in the parental cells
did not fully restore sensitivity to BRAF orMEK inhibitors (Figures
3D–3G). No other secondarymutations or knownmechanisms of
resistance to BRAF or MEK inhibitors were identified in these
cells (Figures S3A–S3C; data not shown).
To further explore the role of MEK2-Q60P and BRAF-V600E
amplification, we overexpressed BRAF-V600E and/or MEK2-
Q60P in parental cells (Figures 3H, 3I, and S3D). Ectopic expres-
sion of BRAF-V600E or MEK2Q60P in Mel1617 cells decreased
sensitivity to PLX4720 (75.4% and 85.9% surviving cells,
respectively). Concomitant expression of BRAF-V600E and
MEK2-Q60P further increased the level of resistance to
PLX4720 (92.4% surviving cells; p = 0.0006 for V600E versus
Q60P plus V600E; p = 0.016 for Q60P versus Q60P plus
V600E; p = 0.358 for Q60P plus V600E versus MR cells). Similar
results were obtained with trametinib. Altogether these data
suggest that concurrent MEK2 mutations and BRAF-V600E
amplification enhance the MAPK pathway and confer resistance
to both BRAF and MEK inhibitors.
MEK2-Q60P and BRAF Amplification Confer Resistance
to the Combination of BRAF and MEK Inhibitors In Vivo
To evaluate the significance of drug resistance in vivo, we in-
jected parental cells, resistant cells, and cells ectopically
expressing MEK2-Q60P at low or high levels into NOD-SCID-
IL2-g-null mice (Figures 4A, 4B, and S4A–S4F). Whereas trame-
tinib inhibited MAPK signaling and growth of tumors derived
from parental cells, it had virtually no effect on drug-resistant tu-
mors or tumors expressing high levels of MEK2-Q60P. Notably,
the combination of trametinib and dabrafenib, although partially
effective in vitro, did not decrease growth of trametinib-resistant
tumors in vivo (Figures 4C and S4G–S4K; data not shown). Anal-
ysis ofMAPK activity in the xenograft tumors showed that neither
single-agent nor the combination therapy affected MAPK sig-
naling in the trametinib-resistant tumors (Figure 4D).Figure 2. A MEK2-Q60P Mutation Decreases Sensitivity to BRAF and M
(A) Chromatogram of Sanger sequencing depicting the de novo Q60P mutation (c
cells resistant to trametinib.
(B) Structure of MEK1 (Protein Data Bank accession number 3EQC) bound to AT
MEK1-Q56P (MEK2-Q60P, red stick) mutation. Only the N-terminal kinase lobe o
stick figures. The figure was generated with PyMol.
(C) 293T cells were mock infected or infected with WT-MEK2 or mutant MEK
immunoblotting.
(D–G) Mel1617 parental cells were mock infected (MI) or infected with a lentiviru
(D and E) Immunoblotting analysis of cells treated with trametinib (Tram) or PLX4
(F and G) Cell viability was determined by MTT assays and calculated relative to
(H–K) Mel1617-MR cells were infected with lentiviral vectors expressing a non
shM2-2). Cell lysates were analyzed by immunoblotting (H and I). Relative cell
mean ± SEM, n = 5.
See also Figure S2 and Table S1.
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levels in the parental cells but not in the resistant cells (Figures
4E, 4F, and S4L–S4M). Persistent MAPK signaling was coupled
to phosphorylation of S6K, whereas inhibition of MAPK blocked
S6K phosphorylation. These data suggest that persistent MAPK
signaling contributes to sustained S6K phosphorylation in the
resistant cells. To determine the therapeutic value of targeting
PI3K/mTOR/S6K in overcoming resistance to BRAF andMEK in-
hibitors, we used a dual PI3K/mTOR inhibitor GSK2126458 (458;
Figure S4N). Resistant xenograft tumors were treated with 458
as a single agent or in combination with dabrafenib and trameti-
nib (Figure 4G). The PI3K/mTOR inhibitor halted the growth of
trametinib-resistant tumors. However, the effect of 458 was
only transient and the tumors resumed growth after 2 weeks of
treatment. In contrast, treatment with a triple combination of
dabrafenib, trametinib, and 458 led to sustained tumor growth
inhibition with no apparent toxicity. Distinguishing between
sustained and transient tumor growth inhibition is important, as
we aim at identifying therapies associated with long-term re-
sponses. Although a double combination with PI3K inhibitors
plus MEK or BRAF inhibitors may work to some extent, it could
be associated with higher toxicity than the triple combination,
as it has been reported that simultaneous treatment with BRAF
and MEK inhibitors is much better tolerated than treatment
with either inhibitor as single agent (Flaherty et al., 2012). These
studies provide proof-of-principle that effective triple combina-
torial strategies targeting two or more pathways can have a
favorable risk benefit profile and should be further explored as
a valuable strategy to treat melanoma and overcome drug
resistance.
Further supporting the clinical relevance of our findings, we
identified the same MEK2-Q60P mutation along with BRAF-
V600E amplification (BRAF-V600E: wild-type ratio of 18:1) in
a patient-derived xenograft tumor generated from a biopsy of a
second melanoma patient who progressed on the combination
of dabrafenib and trametinib (CRPDX; Figures 4H and S4O).
The tumor sample was isolated from a chest wall subcutaneous
metastasis from a BRAF-V600E-melanoma patient enrolled in
the phase I/II of dabrafenib in combination with trametinib and in-
jected subcutaneously into NSGmice. The patient had achieved
a confirmed partial response and progression-free survival of
6 months prior to discontinuation due to disease progression.
Treatment of a short-term culture derived from the CRPDX withEK Inhibitors
.179A > C, p.Q60P) identified in exon 2 ofMAP2K2 in BRAF-V600E melanoma
P and the MEK inhibitor selumetinib (AZD6244) highlighting the position of the
f MEK1 is shown as a cartoon with the ATP and AZD6244 molecules shown as
2-Q60P. Cells were serum starved for 48 hr. Cell lysates were analyzed by
s carrying wild-type MEK2 (WT-M2), or mutant MEK2-Q60P (M2-Q60P).
720 (PLX) for 20 hr.
the untreated cells. Data are represented as mean ± SEM, n = 6.
targeting small hairpin RNA (shRNA) (shNT2) or MEK2 shRNA (shM2-1 and
viability was determined by MTT assays (J and K). Data are represented as
thors
(legend on next page)
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trametinib, dabrafenib, or their combination did not inhibit MAPK
signaling, phosphorylation of S6K, or viability of these cells (Fig-
ures 4H and 4I). Altogether our data suggest that concurrent
MEK2-Q60P mutation and BRAF overexpression can confer
resistance to combined BRAF and MEK inhibition.
DISCUSSION
We identified a de novo MEK2-Q60P mutation and BRAF gain in
a progression sample from a patient resistant to trametinib, a
xenograft tumor-derived from a second patient resistant to the
combination of BRAF and MEK inhibitors, and two melanoma
sublines chronically treated with trametinib. We posit that both
genetic events confer resistance to trametinib and dabrafenib
by increasing MAPK signaling to levels that cannot be inhibited
by BRAF and MEK inhibitors.
Although various mechanisms of resistance to MEK or BRAF
inhibitors have been identified, the contribution of concomitant
mechanisms that sustain addiction to the MAPK pathway and
confer resistance to the combination of BRAF and MEK inhibi-
tors has not been previously reported. AlthoughMEK1mutations
have been previously identified (Emery et al., 2009; Nikolaev
et al., 2012; Wagle et al., 2011), not all MEK1 mutations confer
drug resistance (Shi et al., 2012a; Trunzer et al., 2013) and
MEK2 mutations have not been previously reported in patients
resistant to MEK and/or BRAF inhibitors. Our findings suggest
that prospective analysis of patient samples will need to include
both genetic and genomic characterization of tumors, so that all
potential types of aberrations associated with resistance, such
as concurrent MEK mutations and BRAF amplification, can be
identified. Functional characterization of MEK1/2 mutations
and other genetic events that can alter MAPK signaling output
will provide useful information to guide selection of therapy for
patients with metastatic melanoma.
Combination therapy with BRAF and MEK inhibitors appears
to be more effective than single-agent approaches (Emery
et al., 2009; Greger et al., 2012; Hegedu¨s et al., 2012; Su et al.,
2012; Flaherty et al., 2012); however, this combination could
have limited activity in resistant tumors, particularly in the
context of concurrent resistancemechanisms that hyperactivate
the MAPK pathway. Our studies suggest that this combination is
likely to be more effective if used as first-line therapy before
resistance emerges. Moreover, effective therapies are sorely
needed for patients who progress on BRAF/MEK inhibitors.
Targeting the MAPK pathway downstream of MEK at the level
of ERK, S6K, or RSK is a potential approach to overcome resis-
tance (Hatzivassiliou et al., 2012; Morris et al., 2013). We haveFigure 3. BRAF-V600E Overexpression and Mutant MEK2 Promote Dru
(A) Targeted amplification of the BRAF locus on chromosome 7 demonstrated w
(B) BRAF mRNA levels in Mel1617 and 451Lu sublines assessed by quantitative
(C) BRAF protein levels were analyzed by immunoblotting in parental and resista
(D–G) Mel1617-MR cells were infected with vector control (pLKO.1) or BRAF shRN
by MTT assays (E and G). Data are represented as mean ± SEM (n = 7). Data were
MR-pLK0.1 with Mel1617-MR expressing BRAF shRNA atR100 nM tram (E) or
(H and I) Mel1617 ectopically expressing WT-BRAF, BRAF-V600E or MEK-Q60
trametinib (H) or 1 mMPLX4720 (PLX; I). Cell viability was calculated relative to the
comparing Q60P/V600E with Q60P or V600E and p > 0.05 when comparing Q60
See also Figure S3.
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MEK, and PI3K/mTOR inhibitors led to sustained tumor growth
control, with no overt signs of toxicity. This type of strategy
will need to be further refined and evaluated. Various issues
that could be explored include alternative dose scheduling
(e.g., intermittent dosing; Das Thakur et al., 2013), drug
sequencing, drug combinations comprising specific inhibitors
of downstream targets, and efficacy in tumors bearing other
mechanisms of BRAF- and/or MEK-inhibitor resistance or other
tumor types. Alternative combination strategies, such as the one
we tested, warrant preclinical and clinical investigation as poten-
tial approaches to treat patients refractory to BRAF and MEK
inhibitors.
EXPERIMENTAL PROCEDURES
Detailed experimental procedures are described in the Extended Experimental
Procedures.
Patient Samples
Tumor specimens and clinical information were obtained under institutional
review board-approved studies at the Sarah Cannon Research Institute and
the Hospital of the University of Pennsylvania. Patients provided informed
written consent.
Cell Lines and Viability Assays
Human melanoma sublines Mel1617 and 451Lu were derived from the same
cell line and are BRAF-V600E mutant. WM3942 was derived from a CRPDX
tumor. Cell viability was measured using MTT or Alamar Blue as previously
described (Villanueva et al., 2010).
Western Blotting
Protein lysates were prepared and analyzed as previously described (Villa-
nueva et al., 2010).
All antibodies used were from Cell Signaling Technology except b-Actin,
which was purchased from Sigma-Aldrich, COT and cyclin D1 from Santa
Cruz Biotechnology, and BRAF from Millipore.
MEK2 Constructs, Small Hairpin RNA, and Lentivirus Infection
The MEK2 complementary DNA clone was obtained from OpenBiosystems.
The MEK2-Q60P point mutation was generated using Stratagene’s
QuickChangeII XL site-directed mutagenesis kit (Invitrogen) according to the
manufacturer’s instructions.
Tumor Xenografts
All animal studies were performed in accordancewith institutional guidelines in
NOD/LtSscidIL2Rg-null mice (NSG).
ACCESSION NUMBERS
The Gene Expression Omnibus accession number for the CGH data reported
in this article is GSE49430.g Resistance
ith aCGH in trametinib-resistant cells.
real-time PCR. Data are represented as mean ± SD (n = 6); p < 0.05.
nt sublines.
A. MAPK signaling was assessed by immunoblotting (D and F) and cell viability
analyzed using Wilcoxon rank sum test; p < 0.001 when comparing Mel1617-
R5,000 nM PLX (G).
P, and trametinib-resistant Mel1617 (MR) cells were treated with 0.1 mM of
untreated control. Data are represented as mean ± SEM (n = 6); p < 0.01 when
P/V600E with MR cells treated with PLX.
thors
(legend on next page)
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SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and one table and can be found with this article online at http://dx.
doi.org/10.1016/j.celrep.2013.08.023.
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